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Abstract
Background: Older patients are at an increased risk of developing adverse drug reactions (ADR). Of particular concern are
the oldest old, which constitute an increasingly growing population. Having a validated clinical tool to identify those older
patients at risk of developing an ADR during hospital stay would enable healthcare staff to put measures in place to reduce
the risk of such an event developing. The current study aimed to (1) develop and (2) validate an ADR risk prediction model.
Methods: We used a combination of univariate analysis and multivariate binary logistic regression to identify clinical risk
factors for developing an ADR in a population of older people from a UK teaching hospital. The final ADR risk model was
then validated in a European population (European dataset).
Results: Six-hundred-ninety patients (median age 85 years) were enrolled in the development stage of the study. Ninety-five
reports of ADR were confirmed by independent review in these patients. Five clinical variables were identified through
multivariate analysis and included in our final model; each variable was attributed a score of 1. Internal validation produced
an AUROC of 0.74, a sensitivity of 80%, and specificity of 55%. During the external validation stage the AUROC was 0.73, with
sensitivity and specificity values of 84% and 43% respectively.
Conclusions: We have developed and successfully validated a simple model to use ADR risk score in a population of
patients with a median age of 85, i.e. the oldest old. The model is based on 5 clinical variables ($8 drugs, hyperlipidaemia,
raised white cell count, use of anti-diabetic agents, length of stay $12 days), some of which have not been previously
reported.
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Introduction
Over the next 50 years, many societies throughout the world are
set to face an ‘ageing population’, with its associated burden of
disease and disability. In the US, the proportion of the population
aged 65 years or over in 1998 was 13% [1]. By 2012 that
proportion had risen to 15%, and is projected to rise to 22% by the
year 2060 [2]. The oldest old (those aged 85 or over) will also see a
considerable rise in the size of their population, which is set to
increase from 6 million in 2012 to 18 million in 2060 (an increase
of just under 200%). The picture in the UK is similar. Here, the
oldest old (.85 years) will see the largest relative rise in their
population of over 5 times between the years 1985 and 2035 [3].
Those aged over 65 are the largest consumers of healthcare, and
the recipients of the majority of prescribed medication. It is not
surprising therefore that older people suffer more adverse drug
reactions (ADR) than younger adults, and are 7 times more likely
to require hospitalisation due to an ADR [4]. They are also more
likely to suffer an ADR during inpatient stay. This obviously places
an extreme pressure on healthcare systems, with medical teams
having to treat the consequences of ADRs in addition to the
primary pathology.
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A considerable amount of work has been conducted in the past
30 years to develop risk prediction models for disease, so that
pharmacological, and lifestyle interventions can be targeted to
those in most need (for example the Framingham Heart Study)
[5]. In 1997, McElnay et al identified several risk factors but their
final model, predicting adverse drug events (defined as ADRs and
ineffective treatment), had low accuracy scores and so further
development was halted [6]. In recent years, risk prediction
models for ADRs have begun to emerge, offering healthcare
practitioners a potential tool to assist clinical and therapeutic
decision making, especially in high-risk patient groups such as the
over 65s. Trivalle et al used data from Parisian rehabilitation
hospitals to create a model which focus’ purely on medication as
risk variables [7]. In 2010, the GerontoNet ADR risk score was
published which used a range of clinical and drug-related risk
factors, drawn from an historical database of patients in Italy. This
model was then externally validated using data from across four
European countries [8]. In their validation study, patients had a
mean age of 80.3 years (67.6), and the Area Under the Curve was
0.71 (0.68–0.73). O’Connor et al recently applied the Gerontonet
tool prospectively to a separate cohort of acutely ill patients and
found that it correctly predicted ADR risk in 62% of patients. The
study also identified additional predictors (e.g. renal function, age,
potentially inappropriate medicines, number of medicines) which
they suggest should be included in future tools [9].
Although the majority of risk prediction models developed in
this area have been validated to some extent, the number of events
detected has been relatively small. They have also, in general,
included patients with a wide age-range, and the final models are
arguably impractical for everyday clinical use. The current study
therefore aimed to (1) develop, and (2) validate (using a 4-stage
process) an ADR risk prediction model. Our objectives were to
produce a model that is robust and generalizable across
populations, simple to use, and appropriate for predicting ADR
risk in the oldest old ($85 years). The model was developed from a
prospective and comprehensive assessment of ADR events in a
teaching hospital in Brighton, UK. It was then externally validated
using data collected from centres in Italy, Belgium, the UK, and
the Netherlands.
Methods
The Brighton Dataset
All patients aged $65 years that were admitted to one of 4
wards (2 elderly care and 2 stroke) at Brighton and Sussex
University Hospitals NHS Trust (BSUHT) over two 3-month
study periods (January to March in 2007 and 2008) September
2008 to February 2009) were systematically enrolled into the
study. However, the elderly care wards at BSUHT used in this
study only accept patients $80 years old, which ensured that the
majority of patients enrolled in our study were the oldest old. Most
patients were admitted through either the accident and emergency
department or the acute medical and surgical assessment unit.
Patients were subsequently excluded if they met one of the
following exclusion criteria: admitted following self-poisoning,
transferred to another ward during the weekend, admitted and
discharged during the weekend, died within 24 hours of admission,
or medical notes were not available for further investigation. All
remaining admissions (690) were followed until discharge, and
form the Brighton ADR RIsk Study Dataset (BADRI) [10].
Assessing the presence of an Adverse Drug Reaction
(ADR)
For the purpose of this study we adopted the Edwards and
Aronson definition of an ADR: an appreciably harmful or
unpleasant reaction, resulting from an intervention related to the
use of a medicinal product, which predicts hazard from future
administation and warrants prevention or specific treatment, or
alteration of the dosage regimen, or withdrawal of the product.’
[11]. Suspected ADRs were first identified by the primary
investigator (BT) using the trigger tool methodology which was
first developed by Classen [12], then later scrutinized and updated
by Rozich [13], Resar [14], and Handler [15]. This was
conducted through review of procedure notes, emergency
department notes, physician progress notes, laboratory reports,
physician medication orders on drug charts, nursing flow sheets,
hospital discharge records, and multidisciplinary progress notes.
Additionally, reports of ADRs from health care-providers and
those identified following a review of administrative incident
reports concerning ADRs were also included for further review.
Patients were however not directly consulted by the primary
investigator. All suspected events were then discussed with the
attending hospital physician or hospital pharmacist to confirm
interpretation. Each event was then reviewed by an independent
reviewer (physician) and the primary investigator (pharmacist) to
determine the causal relationship between drug intake and the
suspected ADR. This was conducted using the Hallas algorithm
[16], where each event was classified as either being a definite,
probable, possible or unlikely ADR according to the number of
predefined criteria that were met. The predefined criteria were: 1)
known ADR, 2) reasonable temporal relationship, 3) dechallenge,
4) rechallenge, and 5) no other explanation for the condition. To
further strengthen the methodology, confidence about the
causality assessment for each event was rated by the reviewers
on a 6-point Likert scale devised by Bates and colleagues [17]. The
six point Likert scale consists of: 1 little or no confidence; 2, slight-
to-moderate confidence; 3, less than 50 percent confidence but a
close call; 4, more than 50 percent confident but a close call; 5,
strong confidence; and 6, virtually certain. All events classified as
definite, probable, or possible, and which received .50%
confidence rating (a score of .4) were classified as drug-related
and included in the analysis.
Variables included in the risk prediction model
The following data were collected for each patient included in
the Brighton dataset: basic demographic data (age, gender, and
ethnic origin); admission diagnosis and details of the presenting
complaint; details of previous admissions; length of stay; informa-
tion on social settings (e.g. living alone, smoking and alcohol
history); assessment of cognition (Abbreviated Mental Test Score,
AMTS); assessment of disability (Barthel Index); biochemical and
haematological markers; drug history. We used the WHO
International Statistical Classification of Diseases and Related
Health Problems to classify comorbidities [18], and renal
impairment was taken to be an eGFR ,60 ml/min [19].
All data were obtained within 48 hours of admission to the study
ward from a combination of a review of the medical notes and
through discussion with nursing staff, pharmacists and the medical
team attending the patient.
Statistical analysis
The process of developing the risk prediction model consisted of
2 stages. The first stage involved application of univariate analysis
to generate a framework of variables, or predictors, for developing
BADRI Risk Prediction Model
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an ADR. Those variables which were found to be statistically
significant (p,0.05) were taken forward to the next stage of
multivariate analysis. In addition, variables that were identified in
other studies as being important predictors of ADR (Table 1), but
which had p values .0.05 but ,0.25 were also included in the
multivariate stage (see Hosmer DE, 1989 for further details on this
methodology) [20]. Variables which were present in less than 5%
of the study population were omitted from the analysis due to the
risk of including a statistically significant artefact in the model.
Multivariate analysis was undertaken using binary logistic
regression analysis. First variables were removed from the model
using the backward elimination process. The removal criteria was
set at p = 0.10 to allow variables to be retained in the model for as
long as possible. The process was then repeated with the forward
selection procedure before final confirmation of the model.
Selected candidate variables were later assessed for multicollinear-
ity and association to rule out any strong correlation between two
or more candidate variables in the final model. A p.0.05 from a
x2 test was taken to indicate an association. Following the iteration
process, the retained variables were taken forward into the final
risk model.
The overall fit of the BADRI risk prediction model to the
Brighton dataset was assessed using the Hosmer-Lemeshow test,
and effect size measured using the Nagelkerke R2. The cut-off
BADRI score was determined by first calculating sensitivity
(proportion of true positives) and specificity (proportion of true
negatives) of the model for the range of risk scores (0–5) and then
calculating Youden’s Index (J; Equation 1). Discrimination of the
model was further assessed by an analysis of the area under the
operator curve (AUROC), which assesses the ability of the risk
score to predict ADR. AUROC indicates how well the model
distinguishes patients who do not experience ADR from those with
ADR (Bewick et al., 2005). The AUROC value signifies the
probability that a patient with an ADR had a higher predicted
probability than a patient without ADR. An ideal model would
have an AUROC of 1, whereas a random guess would have an
AUROC of 0.5 [21].
J~(1{a)z(1{b){1 ð1Þ
Where (12a) is Sensitivity and (12b) is Specificity.
Validation
The ADR risk prediction model (BADRI risk score) was
validated in a separate cohort of in-hospital older adults admitted
to four Geriatric or Internal Medicine wards in participating study
centres across Europe. These centres, which contribute to the
European Dataset, were: Catholic University of Sacred Heart,
Rome, Italy; Gent University Hospital, Ghent, Belgium; Erasmus
University Medical Center, Rotterdam, The Netherlands and
BSUH (Brighton, UK). The aim of this part of the study was to
evaluate the reliability of BADRI score locally and also in other
populations.
Patients admitted to these centres between September 2008 and
December 2008 were enrolled and followed up until discharge or
death. Exclusion criteria were identical to the Brighton Dataset
with the addition of patients receiving current chemotherapy. In
accordance with the methods described above, data for all
variables included in the model (along with a selection of other
variables, e.g. Mini Mental State Examination MMSE) were
recorded for each patient, along with details of any suspected
ADR. In an attempt to standardise the information being collected
from the various European centres, the Naranjo algorithm was
used to assess causality of reported ADR in this instance as it has
evidence for inter-observer reliability [22]. Only events classified
as definite (score, 9–12 points) or probable (score, 5–8 points) were
considered to have been drug-related in the validation part of this
study. Pair assessment was not conducted for the validation
dataset.
As with assessment of the model in the Brighton dataset,
sensitivity and specificity, Youden’s Index, and AUROC were
calculated on the data gathered from the validation cohort.
Ethics
Ethical approval for conducting the validation component of
this research was obtained from Brighton West Research Ethics
Committee, UK (reference number: 08/H1111/43). Written
informed consent was given by participants (or next of kin/
caregiver) for the validation component of this study. For all stages
of this research, patient records/information were anonymized
and de-identified prior to analysis.
Results
Patients
The initial Brighton dataset study population comprised 946
patients. Two-hundred and fifty-six of these patients were
excluded in the final analysis because they were either younger
than 65 years old (111 {43%} patients), or were rapidly discharged
or died before the end of the study period (145 {57%} patients).
Patient recruitment was further hindered by an outbreak of
Norovirus and Clostridium difficile infection on two of the study
wards which restricted access to patients on the grounds of
Table 1. Predictor variables identified from the univariate
analysis stage, and from other studies, only 8 of which were
taken forward to the multivariate analysis stage (indicated
with *).
Variables identified in univariate analysis
Hyperlipidaemia*
Number of medication $8*
Length of stay $12 days*
Use of anti-diabetic agents*
High white blood cell count on admission*
Diabetes
Arthritis/osteoarthritis
Antihypertensives
Opioid analgesics
Angiotensin converting enzymes inhibitors
b-blockers
Cardiac glycosides
Anti-infective medicines
Variables identified in other studies
History of previous ADR* [8,28]
Number of co-morbidities $4* [29]
Drugs with a narrow therapeutic index* [27,30]
Congestive cardiac failure [31]
Liver failure [32,33]
All variables are binary, and not continuous.
doi:10.1371/journal.pone.0111254.t001
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infection control. Consequently, 690 patients formed the final
Brighton dataset (Figure 1).
The mean age of patients in the Brighton dataset was 84.3 years
(range 65–103; median 85; inter-quartile range 81–89), with a
larger proportion of the cohort being female (61%) than male. The
mean number of regular medications (taken daily, including
topical preparations) taken on admission by these patients was 5.9
(range 0–18; median 6; IQR: 3–8). The presence and burden of
co-morbidities was high, with the mean number of recorded co-
morbidities in this study sample being 8.03 (range 1–17; median 8;
IQR: 6–10). Table 2 provides details of the common co-
morbidities found in this patient group. Forty one percent of
patients were widowed, 35% married, 61% lived in a house or flat
and 10.6% were living in nursing homes. Almost 57% (n= 381) of
the total patients were living alone and half of them required a
degree of social support.
Following the initial assessment of patient histories, 95 cases of
ADR, in 86 patients were identified in the Brighton dataset
(12.5%). An assessment of causality was then conducted using the
Hallas algorithm, which rated 23 of these cases as definite (24.2%),
47 as probable (49.5%), and 25 cases as possible (26.3%). All 95
events also received confidence rating of .50% (score .3) and so
were retained for subsequent analysis of the Brighton dataset. The
drugs classes with highest frequency of reported ADRs were
cardiovascular, analgesic and anti-diabetic. A detailed analysis of
the types, severity, and preventability of the ADRs have been
published elsewhere [10].
Development of the BADRI risk model
Thirteen variables showing a significant difference in prevalence
between ADR and non-ADR patients were identified from the
univariate analysis and taken forward to the next stage of model
development (Table 1). A further 5 variables showing minimal
association in this dataset (p,0.25), but which had been identified
as important in predicting ADR risk by other studies, were also
included at this stage. This differs from the methodology used by
GerontoNet, but supplementing the model with additional
clinically plausible variables is nonetheless an accepted technique
[20]. For the continuous predictor variables, multicolinearity tests
found no significant associations, and so these variables were
retained in the model. Of the remaining binary variables, ten were
found to be correlated and were subsequently discarded. This
resulted in a total of 8 variables being taken forward to the
multivariate analysis stage (Table 1).
Application of both the backward and forward stepwise
elimination procedure during multivariate analysis identified 5/8
variables that contributed significantly to the risk of developing an
ADR (Wald test scores, p,0.1; Table 3). The Hosmer-Leme-
show test showed that the fit was satisfactory (x2 = 4.196, 7 degrees
of freedom, p= 0.757); however, the Nagelkerke R2 value was low
(0.16), indicating a small effect size. Although small, the model
provides more information about ADR risk compared to a model
with no predictors. All 5 variables were subsequently used to form
the final BADRI risk model.
The ability of the BADRI risk model to predict ADR in the
Brighton dataset
Following development of the BADRI risk model, we attributed
an ADR risk score to each patient in the Brighton dataset based of
the number of variables present. For simplicity, an equal weighting
of 1 was attributed to each variable. The range of the risk scores
for patients in the Brighton dataset was 0–5, with a mean of 1.5,
standard deviation of 1.05, and a median of 1. When grouped
according to BADRI risk model, there was a clear relationship
between risk score, and the proportion of ADRs (Figure 2A).
To maximise the accuracy of the model in predicting ADRs in
patients, we performed a further analysis to determine the most
appropriate cut-off risk score. This was done by calculating the
sensitivity (true positive) and specificity (true negative) of the model
using each risk score (0–5) as a cut-off value, and then calculating
Youden’s Index (Table 4); the greater the index the more
discriminatory the model at the specified cut-off value. Youden’s
Figure 1. Recruitment diagram for the Brighton and Validation datasets.
doi:10.1371/journal.pone.0111254.g001
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Table 2. Patient characteristics and co-morbidities in the Brighton and validation (European) data sets.
No (%) of patientsy
Median (interquartile range)
Demographics BADRI dataset (n = 690) Validation dataset (n = 483)
Age (yr)y 85 (81–89) 80 (75–86)
Gender (Female) 419 (61) 279 (57.8)
Ethnic Origin (White-British) 607 (88)
Clinical
Length of Stayy 12 (7–19) 10 (6–17)
Co-morbiditiesy 8 (6–10)
Barthel Activity of daily Livingy 19 (14–20)
Katz Activity of Daily Livingy 1 (0–4)
Glasgow Coma Scaley 15 (14–15)
Cognition (AMTS)y 6 (3–9)
Cognition (MMSE)y 26 (22–28)
Previous Hospital Admission 168 (25)
Social
Smoking 59 (8)
Alcohol 183 (41)
Living Alone 383 (57)
Drug Related
Number of regular
medications on admissiony
5 (3–7) 5 (4–8)
Number of regular
medications on the wardy
7 (5–10) 9 (6–14)
Previous drug allergies 149 (22)
Previous History of ADR 263 (38) 173 (35.8)
Co-morbidities
Hypertension 502 (72.8) 305 (63.1)
Infection (UTI/Chest infection) 303 (43.9) 125 (25.9)
Anaemia 283 (41) 135 (28)
Arthritis/Osteoarthritis 280 (40.6)
Renal impairment
(,60 mLs/min)
248 (35.9) 66 (13.7)
Fall 209 (30.3) 114 (23.8)
Depression 176 (25.5)
Confusion 176 (25.5)
Ischemic Heart Disease 159 (23)
Atrial Fibrillation 156 (22.6)
Asthma/COAD 135 (19.6)
Malignancy 133 (19.3)
Diabetics 115 (16.7) 131 (27.1)
Previous stroke 115 (16.7)
Previous TIA 110 (15.9)
Osteoporosis 86 (12.5)
Hyperlipidaemia 284 (12.2) 135 (28)
Congestive Heart Failure 70 (10.1) 67 (13.9)
Dementia
(other than Alzheimer)
74 (10.7)
Alzheimer 25 (3.6)
Liver diseases 7 (1) 30 (6.2)
Abbreviations: Mini-Mental State Examination, MMSE; Abbreviated Mental Test Score, AMTS; Unrinary Tract Infection, UTI; Chronic Obstructive Airways Disease, COAD;
Transient Ischaemic Attack, TIA; Adverse Drug Reaction, ADR.
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Index was found to be greatest when the cut-off score was .1
(J = 0.36; sensitivity and specificity were 80%, and 55% respec-
tively. Performance of the ADR risk model was also assessed from
a calculation of the area under the receiver operator curve
(AUROC). The model was found to have an AUROC of 0.74
(95% CI 0.68 to 0.79, Figure S1), suggesting that the ability of the
BADRI model to predict ADRs is better than chance alone (0.5).
Validation
Validation of the BADRI risk model was conducted on patient
data gathered from 4 European centres (the European dataset).
Four-hundred and eighty-three patients were recruited, with a
mean age of 80.3 years (range 65–99; median 80; inter-quartile
range 75–86), and mean number of drugs taken during hospital
stay of 1167.0. ADRs were observed in 56 patients (11.6%).
All variables that form the BADRI risk model, with the
exception of raised white cell count were associated with increased
rates of ADR in patients that comprise the European dataset.
When grouped according to ADR risk score, a similar relationship
between risk score and the proportion of ADRs, to that seen in the
Brighton dataset was observed (Figure 2B). As with the Brighton
dataset, a cut-off score of .1 provided the best discrimination
between individuals that progressed to suffer an ADR and those
that did not (J = 0.26, sensitivity and specificity values of 84% and
43% respectively, Table 5). The BADRI risk model also
demonstrated an acceptable capacity to discriminate in the
European dataset, with an AUROC of 0.73 (95% CI 0.66–0.80,
Figure S1), indicating that it is statistically useful in predicting
ADR not only when applied in the local area (Brighton), but also
in other populations.
Discussion
We have produced an ADR risk prediction model, based on 5
clinical variables, which is able to identify older patients that have
an increased likelihood of developing an ADR. The model was
developed using data gathered from a population of patients in the
UK with a median age of 85 years, which makes this the first study
to address ADR risk specifically in the oldest old, a proportion of
the US and UK population which is increasingly growing. The
BADRI risk prediction model has been successfully validated in
older patients (although not the oldest old) from hospitals across
continental Europe, showing that it is a reasonably robust model,
that may be applied to patients from other geographical locations,
and perhaps from different healthcare systems with a similar
demographic. The final BADRI risk prediction model contains
only a small number of variables, and each one is given the same
score (1 in each case), making it relatively simple to use. This may
make its adoption into routine clinical practice easier.
The BADRI score was found to have acceptable goodness of fit
and good discrimination performance when applied to both
Brighton and European datasets. An AUROC of greater than 0.7
for the model showed that it has acceptable discrimination
capacities for patient with ADRs as compared to patients who did
not experience an ADR. The sensitivity of 80% indicates that the
model, in its present form, is a satisfactory predictor of ADR.
However, the low specificity (46%) means that the model may
incorrectly label patients ‘at risk of an ADR’ who will not
ordinarily go on to experience such an event. A false positive in
this instance may have implications for the patient’s management.
For example, important treatments may unnecessarily be withheld
based on inaccurate risk stratification. In addition, inappropriately
labelling patients as risky when they are not may result in the
inefficient use of resources due to increased monitoring.
A direct comparison of the BADRI score with the recently
developed GerontoNet risk score [8] show that both perform
similarly on levels of discrimination (0.71, GerontoNet vs. 0.74,
BADRI). The sensitivity value for the BADRI model during
development was 80%, exceeding that of GerontoNet at 68%,
indicating that BADRI performs better at detecting patients that
go on to have an ADR. However, its specificity value (or true
negative) of 55%, was lower than GerontoNet’s at 65%. It must be
noted however, that GerontoNet only considered cases of definite
and probable ADRs for inclusion in their study, whereas possible
ADRs were included in the present study. Other studies which
have attempted to develop predictive models for adverse drug
events have not been externally validated which restricts their
applicability to other populations.
Much work has been conducted over recent years to identify
clinical risks associated with ADR. Interestingly, a number of these
risks were not found to be significant predictors of ADR in this
current study. For example, well known factors such as age [23],
previous history of ADR, gender [24], heart failure [8], prior
bleeding on admission [25], renal impairment [26], the use of
certain drug classes [27], and abnormalities in certain laboratory
parameters [6] were not retained in our final model. The omission
of these previously identified risk factors could possibly be
explained by the inclusion criteria, which recruited a broader
range of ages. Of the variables included in our final model, the
number of medications prescribed during inpatient stay was the
only variable that has been consistently identified as an ADR risk
in all other validated studies. One variable previously identified by
doi:10.1371/journal.pone.0111254.t002
Table 3. Results of multivariate analysis.
Final variables B S.E Wald Sig. OR 95% CI
Hyperlipidemia 1.199 0.309 15.093 ,0.001 3.316 1.811–6.072
Number of medication $8 1.194 0.274 18.922 ,0.001 3.300 1.927–5.651
Length of stay $12 days 0.819 0.267 9.441 0.002 2.269 1.345–3.826
Use of anti-diabetic agents 0.645 0.309 4.352 0.037 1.906 1.040–3.493
High WCC on admission 0.437 0.254 2.953 0.086 1.548 0.940–2.548
Constant -3.628 0.316 131.769 1 0.000 0.027
(WCC=White Cell Count).
doi:10.1371/journal.pone.0111254.t003
BADRI Risk Prediction Model
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O’Connor et al to predict ADR risk is that of potentially
inappropriate medicines. These were not included in this study
as this variable was identified after our study had been conducted
[9].
This is the first study to include total length of stay,
hyperlipidaemia and white cell count as ADR risk factors. Length
of stay may be a proxy measure for the severity of the patients’
underlying illness, perhaps reflecting an increase in the number of
prescribed medicines (with associated risk of drug interactions).
However, the fact that the number of medications prescribed is
also included as a risk factor in the BADRI model, and that, when
tested, no association between the two variables was found,
suggests that they represent different mechanisms. Alternatively,
an increased length of stay may reflect a deterioration in the
patients clinical state, and a change in the pharmacokinetic (for
example, renal and hepatic function, nutritional status) or
pharmacodynamic (tissue sensitivity) profile of the medication,
leading to altered drug levels or response. It is also conceivable
that a prolonged hospitalisation could increase the likelihood of
experiencing, and detecting, an ADR, i.e. a posteriori observation,
which questions the value of this variable as a useful predictor.
We also found that a diagnosis of hyperlipidaemia significantly
increased the likelihood of developing an ADR. The reason for its
identification as a risk factor has yet to be determined, but may
simply reflect the fact that individuals with a history of an
abnormal lipid profile are at higher risk of cardiovascular disease,
and as a consequence, may be receiving multiple drug therapies.
An association between a high white blood cell count on admission
and ADR risk was another novel risk factor identified in the
current study. This may reflect that the patient is suffering from an
infection or inflammatory condition (for example, post myocardial
infarction or pulmonary embolism) which requires the subsequent
use of potential harmful antibiotics or cardiac medications.
Regardless of the cause of raised WCC, it is nonetheless a marker
for increased susceptibility to ADR, and will alert the clinician to
the patients increase risk of developing an adverse reaction to a
medicine.
Although there are several advantages of the BADRI score in
predicting ADR risk, there are of course some limitations that
need to be addressed. Causality assessment for ADR in the testing
dataset was conducted using Naranjo’s algorithm, however, during
the initial development of the model (Brighton dataset), the Hallas
criteria was utilised to determine causality. It is therefore plausible
that the use of different criteria might affect the outcome of the
study. However, in addition to the Hallas criteria, we asked
reviewers to rate causality as being a drug cause on a Likert scale,
Figure 2. ADR rate according to ADR risk score. The BADRI risk model was applied to all 690 patients from the Brighton dataset (A), and 483
patients from the European dataset (B). The ADR rate is calculated as the proportion of patients in each scoring category that suffered an ADR. For
both datasets there is a general increase in the ADR rate as the risk score increases.
doi:10.1371/journal.pone.0111254.g002
Table 4. Accuracy of the BADRI risk model as applied to the Brighton dataset using various cut-off values (risk scores).
Risk
Score
Patients
with ADR
Patients
without ADR Sensitivity Specificity
Youden’s
index (J) 1-specificity
.0 84 486 0.98 0.20 0.17 0.80
.1 69 269 0.80 0.55 0.36 0.45
.2 34 89 0.40 0.85 0.25 0.15
.3 9 14 0.10 0.98 0.08 0.02
.4 2 0 0.02 1.00 0.02 0.00
Note Youden’s Index is largest when the cut-off value is .1 (with sensitivity of 80% and specificity of 55%).
doi:10.1371/journal.pone.0111254.t004
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and also included all classifications of ADR (definite, probable and
possible) in our final model, so we can be reasonably confident that
ADR were classified appropriately. Another limitation of this study
is the generalizability of the findings. The current tool was
validated in four European countries and may not therefore be
applicable to countries outside Europe.
The results of this study may also be subject to a small extent of
information bias, especially in the validation study group.
Information bias occurs when data collected from patients is
pursued more aggressively in one group or recorded differently
than in another. In addition, there might also be a tendency to
recall bias (another form of information bias). Older patient
populations have a higher incidence of memory impairment which
could affect the quality of the data collected. However, careful
evaluation and extraction of information from the patient notes
reduces the chance of recall bias in this study.
Although this study has identified a number of variables which
predict ADR in some older patients, as a model, the BADRI risk
score needs further development before it can be adopted for use
in routine clinical practice. The reasons for this are (1) we have yet
to establish whether clinical judgement alone is more accurate
than the BADRI score at identifying those individuals who go on
to develop an ADR (2) despite BADRI being relatively simple to
use by our experienced researchers, we have yet to test the
usability of the model by clinicians (3) we have yet to determine
whether introducing this model into routine practice would
improve the safety profile of medication use in older patients,
and also whether there are any humanistic and cost implications.
Conclusion
The development of the BADRI score, which consists of five
variables for predicting ADR in older patients, was chosen using a
stepwise selection procedure. The predictors were chosen based on
the combination of statistically significant tests and also by
consideration of the biological plausibility and conceptual appro-
priateness of the variables. External validation conducted in
different locations retained the fitting and also the predictive
power of the model which ensure the generalisability of the score.
The BADRI score consists of different risk predictors compared to
the GerontoNet risk score besides the number of medication, yet it
offers a scoring system that is simple to apply with limited
computational involvement, whilst providing the same discrimi-
nation performance.
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